KR100926596B1 - 뉴클레오시드 유도체 및 그의 치료 용도 - Google Patents
뉴클레오시드 유도체 및 그의 치료 용도 Download PDFInfo
- Publication number
- KR100926596B1 KR100926596B1 KR1020067022856A KR20067022856A KR100926596B1 KR 100926596 B1 KR100926596 B1 KR 100926596B1 KR 1020067022856 A KR1020067022856 A KR 1020067022856A KR 20067022856 A KR20067022856 A KR 20067022856A KR 100926596 B1 KR100926596 B1 KR 100926596B1
- Authority
- KR
- South Korea
- Prior art keywords
- tumors
- compound
- tumor
- formula
- pharmaceutically acceptable
- Prior art date
Links
- 0 *[C@]1[C@](*(C=C(*)C(N2)=O)C2=O)C(F)=C(CO)C1 Chemical compound *[C@]1[C@](*(C=C(*)C(N2)=O)C2=O)C(F)=C(CO)C1 0.000 description 2
- QLLGKCJUPWYJON-ASODMVGOSA-N NC(C=CN1C([C@@H]2O)C(F)=C(CO)[C@H]2O)=NC1=O Chemical compound NC(C=CN1C([C@@H]2O)C(F)=C(CO)[C@H]2O)=NC1=O QLLGKCJUPWYJON-ASODMVGOSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (19)
- 삭제
- 제1항에 있어서, 제약상 허용되는 담체 또는 희석제를 추가로 포함하는 제약 조성물.
- 제1항에 있어서, 상기 종양이 난소 종양, 유방 종양, 자궁경부 종양, 전립선 종양, 간 종양, 폐 종양, 신장 종양, 결장 종양, 췌장 종양, 뇌 종양, 위 종양 및 흑색종으로부터 선택된 것인 제약 조성물.
- 치료 유효량의 제9항의 화합물 또는 그의 제약상 허용되는 염, 및 제약상 허용되는 담체 또는 희석제를 포함하는 제약 조성물.
- 제9항에 있어서, 난소 종양, 유방 종양, 자궁경부 종양, 전립선 종양, 간 종양, 폐 종양, 신장 종양, 결장 종양, 췌장 종양, 뇌 종양, 위 종양 및 흑색종으로부터 선택된 종양에 대한 하나 이상의 세포주에 대해 10 μM 이하의 IC50 값을 갖는 화합물.
- 제14항에 있어서, 상기 세포주가 난소 종양에 대한 인간 OVCAR-3; 유방 종양에 대한 MCF-7 또는 MDA-MB-231; 자궁경부 종양에 대한 HeLa; 전립선 종양에 대한 PC3 또는 LNCap; 간 종양에 대한 HepG2; 폐 종양에 대한 A549 또는 NCI-H226; 신장 종양에 대한 UMRC2; 결장 종양에 대한 HT-29 또는 HCT116; 췌장 종양에 대한 PANC-1; 뇌 종양에 대한 U251; 위 종양에 대한 MKN-45; 및 흑색종에 대한 SK-MEL-28로부터 선택된 것인 화합물.
- 제14항에 있어서, IC50 값이 1.0 μM 이하인 화합물.
- 제14항에 있어서, IC50 값이 0.5 μM 이하인 화합물.
- 제18항에 있어서, B가 트리틸인 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55814104P | 2004-04-01 | 2004-04-01 | |
US60/558,141 | 2004-04-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070012685A KR20070012685A (ko) | 2007-01-26 |
KR100926596B1 true KR100926596B1 (ko) | 2009-11-11 |
Family
ID=34979006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067022856A KR100926596B1 (ko) | 2004-04-01 | 2005-04-01 | 뉴클레오시드 유도체 및 그의 치료 용도 |
Country Status (15)
Country | Link |
---|---|
US (1) | US7405214B2 (ko) |
EP (1) | EP1732902B1 (ko) |
JP (2) | JP5001832B2 (ko) |
KR (1) | KR100926596B1 (ko) |
CN (2) | CN102091072A (ko) |
AT (1) | ATE453628T1 (ko) |
AU (1) | AU2005230676B2 (ko) |
BR (1) | BRPI0509553B8 (ko) |
CA (1) | CA2562965C (ko) |
DE (1) | DE602005018620D1 (ko) |
ES (1) | ES2334803T3 (ko) |
IN (1) | IN2014DN04587A (ko) |
MX (1) | MXPA06011141A (ko) |
PL (1) | PL1732902T3 (ko) |
WO (1) | WO2005097757A2 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9315534B2 (en) * | 2007-08-10 | 2016-04-19 | Board Of Regents Of The University Of Nebraska | Radiologic agents for monitoring alzheimer's disease progression and Evaluating a Response to Therapy and processes for the preparation of such agents |
US20120269725A1 (en) * | 2009-12-23 | 2012-10-25 | Janine Baranowska-Kortylewicz | Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer |
ES2913214T3 (es) | 2013-03-15 | 2022-06-01 | Rexahn Pharmaceuticals Inc | Proceso para la preparación de 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihidroxi-3-hidroxi-metil-ciclopent-2-enil)-1H-pirimidin-2-ona |
EP3307251B8 (en) | 2015-06-09 | 2021-12-01 | Ocuphire Pharma, Inc. | Fluorocyclopentenylcytosine uses and processes of preparation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032920A2 (en) * | 2000-10-18 | 2002-04-25 | Pharmasset Limited | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6187674A (ja) * | 1984-10-06 | 1986-05-06 | Yoshitomi Pharmaceut Ind Ltd | シクロペンテン環を有する新規ヌクレオシド |
US4975434A (en) * | 1986-05-27 | 1990-12-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antiviral and anticancer cyclopentenyl cytosine |
TWI299664B (en) * | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
-
2005
- 2005-04-01 BR BRPI0509553A patent/BRPI0509553B8/pt active IP Right Grant
- 2005-04-01 CA CA2562965A patent/CA2562965C/en active Active
- 2005-04-01 MX MXPA06011141A patent/MXPA06011141A/es active IP Right Grant
- 2005-04-01 EP EP05733004A patent/EP1732902B1/en active Active
- 2005-04-01 AT AT05733004T patent/ATE453628T1/de not_active IP Right Cessation
- 2005-04-01 WO PCT/US2005/011313 patent/WO2005097757A2/en active Application Filing
- 2005-04-01 ES ES05733004T patent/ES2334803T3/es active Active
- 2005-04-01 KR KR1020067022856A patent/KR100926596B1/ko active IP Right Grant
- 2005-04-01 US US11/095,686 patent/US7405214B2/en active Active
- 2005-04-01 JP JP2007506347A patent/JP5001832B2/ja active Active
- 2005-04-01 AU AU2005230676A patent/AU2005230676B2/en active Active
- 2005-04-01 CN CN2010105546004A patent/CN102091072A/zh active Pending
- 2005-04-01 DE DE602005018620T patent/DE602005018620D1/de active Active
- 2005-04-01 PL PL05733004T patent/PL1732902T3/pl unknown
- 2005-04-01 IN IN4587DEN2014 patent/IN2014DN04587A/en unknown
- 2005-04-01 CN CN2005800178253A patent/CN1980898B/zh active Active
-
2012
- 2012-03-12 JP JP2012054597A patent/JP2012107072A/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032920A2 (en) * | 2000-10-18 | 2002-04-25 | Pharmasset Limited | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
Non-Patent Citations (2)
Title |
---|
CANADIAN JOURNAL OF CHEMISTRY, NATIONAL RESEARCH COUNCIL. OTTAWA, CA, vol. 70, no. 4, pages 1162-1169, 1992. |
JOURNAL OF MEDICINAL CHEMISTRY. vol. 46, no. 2, pages 201-203, 2003.01.16. |
Also Published As
Publication number | Publication date |
---|---|
BRPI0509553A (pt) | 2007-09-18 |
CN1980898B (zh) | 2011-01-12 |
ES2334803T3 (es) | 2010-03-16 |
AU2005230676B2 (en) | 2010-10-07 |
CN102091072A (zh) | 2011-06-15 |
PL1732902T3 (pl) | 2010-06-30 |
MXPA06011141A (es) | 2007-08-14 |
ATE453628T1 (de) | 2010-01-15 |
DE602005018620D1 (de) | 2010-02-11 |
CN1980898A (zh) | 2007-06-13 |
BRPI0509553B1 (pt) | 2019-06-18 |
JP2007531736A (ja) | 2007-11-08 |
EP1732902A2 (en) | 2006-12-20 |
US7405214B2 (en) | 2008-07-29 |
AU2005230676A1 (en) | 2005-10-20 |
EP1732902B1 (en) | 2009-12-30 |
CA2562965C (en) | 2013-10-29 |
JP5001832B2 (ja) | 2012-08-15 |
CA2562965A1 (en) | 2005-10-20 |
BRPI0509553B8 (pt) | 2021-05-25 |
JP2012107072A (ja) | 2012-06-07 |
WO2005097757A2 (en) | 2005-10-20 |
KR20070012685A (ko) | 2007-01-26 |
IN2014DN04587A (ko) | 2015-07-10 |
US20050222185A1 (en) | 2005-10-06 |
WO2005097757A3 (en) | 2005-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100942865B1 (ko) | 퀴나졸린 유도체 및 이의 치료적 용도 | |
AU2017273117B2 (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
KR101441770B1 (ko) | 신규 5-플루오로우라실 유도체 | |
MX2007007228A (es) | Profarmaco de amida de gemcitabina, composiciones y uso del mismo. | |
AU2009292555B2 (en) | Novel prostaglandin I2 derivative | |
CN107382966B (zh) | 一类荜茇酰胺-川芎嗪杂合物、制备方法及医药用途 | |
EP3381474A1 (en) | Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy | |
KR20070011457A (ko) | 신규 수용성 프로드럭 | |
KR100926596B1 (ko) | 뉴클레오시드 유도체 및 그의 치료 용도 | |
CA2792403C (en) | 7,7-difluoroprostaglandin i2 derivative for the prophylaxis or treatment of an ep4 agonist and mediated disease | |
JPWO2005018674A1 (ja) | イムノグロブリン遺伝子の転座を伴う疾患の治療薬 | |
Antoszczak et al. | Differences in Antiproliferative Activity Between Salinomycin-AZT Conjugates Obtained via ‘Click’and Esterification Reactions | |
RU2768451C1 (ru) | Селективный антагонист рецепторов типа A2A | |
JPS62919B2 (ko) | ||
RU2765472C1 (ru) | Средство, обладающее противоопухолевым действием в отношении опухоли легких | |
JPH02304058A (ja) | キサントシリンxモノメチルエーテル誘導体及びそれを含有する抗腫瘍剤 | |
EP4331614A1 (en) | Use of medicament in treatment of tumor disease | |
JP2021028301A (ja) | 皮膚炎治療剤 | |
JPH06298739A (ja) | 低酸素性細胞放射線増感剤 | |
JPWO2019159868A1 (ja) | 大腸炎改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121023 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20131023 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20141023 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20151023 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20161024 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20171020 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20181023 Year of fee payment: 10 |